Clinical trials in Majadahonda – page 19

470 clinical trials in Majadahonda, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Majadahonda at a glance

470

clinical trials

Research sites1

Quick filters

470 trials in Majadahonda

Open in trial search

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Choroidal neovascularisation

Not recruiting

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Faricimab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Small cell lung cancer

Not recruiting

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

InvestigationalNo placebo

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Sponsor:Shanghai Henlius Biotech Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cobolimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:BioNTech SE

Contact Research Centre

Pulmonary arterial hypertension

Not recruiting

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Sotatercept
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:BioNTech SE

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Parkinson's disease

Not recruiting

Study of IPX203 compared to levodopa/carbidopa in patients with advanced Parkinson's disease and motor fluctuations

Registered drugNo placebo

Study of IPX203 compared to levodopa/carbidopa in patients with advanced Parkinson's disease and motor fluctuations

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Levodopa
Sponsor:Zambon Biotech S.A.

Contact Research Centre

Cardiac amyloidosis

Not recruiting

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Novo Nordisk A/S

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Majadahonda

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on ATTR amyloid cardiomyopathy, evaluating new therapeutic approaches for both hereditary and wild-type variants of this heart condition.

Heart Disease Management
Cardiac Function Assessment
Disease Markers Evaluation

Multiple trials testing novel compounds to improve patient outcomes and quality of life.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting urinary tract infections and various herpes virus strains, including studies on both prevention and treatment.

UTI Prevention
Herpes Zoster Protection
Immunotherapy Development

Focus on long-term efficacy and immune response in different age groups.

03 Oncology Studies

Advanced research in multiple cancer types, including prostate cancer, gastric cancer, and lymphomas, with emphasis on targeted therapies and combination treatments.

Metastatic Disease Treatment
Novel Drug Combinations
Immunotherapy Approaches

Investigating breakthrough treatments for various stages of cancer progression.

04 Neurological Disorders

Pioneering research in cerebral ischemic stroke and multiple sclerosis, evaluating innovative treatments to improve patient outcomes and disease management.

Stroke Treatment
Progressive MS Management
Functional Recovery

Focus on both acute interventions and long-term disease modification.

Back to Spain All countries